Efficacité et tolérance d’une nouvelle formulation oculaire de lévocabastine sans conservateur (Levofree®) évaluées lors d’un test de provocation conjonctivale

Allaire, Catherine; Siou-Mermet, Raphaële; Bassols, Ángel

doi:10.1016/j.jfo.2011.08.016

Cited by 6 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, one group reported the presence of parabens in biopsies of breast tumours although no link could be established between parabens and oncogenesis [2,3]. Other studies have shown that benzalkonium chloride is toxic for the cornea and causes ocular inflammation and dry eyes [4][5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Optimising concentrations of antimicrobial agents in pharmaceutical preparations: Case of an oral solution of glycerol and an ophthalmic solution containing cysteamine

Wai

Becasse

Tworski

et al. 2014

Annales Pharmaceutiques Françaises

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Optimising concentrations of antimicrobial agents in pharmaceutical preparations: Case of an oral solution of glycerol and an ophthalmic solution containing cysteamine

Wai

Becasse

Tworski

et al. 2014

Annales Pharmaceutiques Françaises

View full text Add to dashboard Cite

Allergic Conjunctivitis Management: Update on Ophthalmic Solutions

Leonardi,

Quintieri,

Presa

et al. 2024

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of Review The aim of this review, is to present an updated revision of topical management of SAC and PAC, based on the available scientific evidence and focused on the impact of ophthalmic solution formulations on eye surface. Recent Findings Physicians treating ocular allergy should be aware of tear film and tear film disruption in SAC and PAC, and how eye drop composition and additives affect the physiology of the allergic eye. Summary Seasonal and perennial allergic conjunctivitis (SAC and PAC) are the most frequent causes of ocular allergy (OA), and both conditions are underdiagnosed and undertreated. SAC and PAC are immunoglobulin E (IgE)-mediated hypersensitivity reactions. The additional tear film disruption caused by the release of inflammatory mediators increases and exacerbates the impact of signs and symptoms and may trigger damage of the ocular surface. Comorbidities are frequent, and dry eye disease in particular must be considered. Clinical guidelines for the management of SAC and PAC recommend topical therapy with antihistamines, mast cells stabilizers or dualaction agents as first-line treatment, but care should be taken, as many medications contain other compounds that may contribute to ocular surface damage.

show abstract

Ocular benzalkonium chloride exposure: problems and solutions

Goldstein¹,

Silva²,

Blender³

et al. 2021

Eye

117

View full text Add to dashboard Cite

Preservatives in multidose formulations of topical ophthalmic medications are crucial for maintaining sterility but can be toxic to the ocular surface. Benzalkonium chloride (BAK)—used in approximately 70% of ophthalmic formulations—is well known to cause cytotoxic damage to conjunctival and corneal epithelial cells, resulting in signs and symptoms of ocular surface disease (OSD) including ocular surface staining, increased tear break-up time, and higher OSD symptom scores. These adverse effects are more problematic with chronic exposure, as in lifetime therapy for glaucoma, but can also manifest after exposure as brief as seven days. Multiple strategies are available to minimize or eliminate BAK exposure, among them alternative preservatives, preservative-free formulations including sustained release drug delivery platforms, and non-pharmacological therapies for common eye diseases and conditions. In this paper, we review the cytotoxic and clinical effects of BAK on the ocular surface and discuss existing and emerging options for ocular disease management that can minimize or eliminate BAK exposure.

show abstract

Efficacité et tolérance d’une nouvelle formulation oculaire de lévocabastine sans conservateur (Levofree®) évaluées lors d’un test de provocation conjonctivale

Cited by 6 publications

References 25 publications

Optimising concentrations of antimicrobial agents in pharmaceutical preparations: Case of an oral solution of glycerol and an ophthalmic solution containing cysteamine

Optimising concentrations of antimicrobial agents in pharmaceutical preparations: Case of an oral solution of glycerol and an ophthalmic solution containing cysteamine

Allergic Conjunctivitis Management: Update on Ophthalmic Solutions

Ocular benzalkonium chloride exposure: problems and solutions

Contact Info

Product

Resources

About